Dr. Pusztai on Challenges With Neoadjuvant HER2 Therapy

Lajos Pusztai, MD, professor of medicine, chief of Breast Medical Oncology, Yale Cancer Center and Yale School of Medicine, discusses the challenges facing neoadjuvant treatment of patients with HER2-positive breast cancer

Pusztai says that one of the biggest challenges is understanding which patient needs what treatment—pertuzumab (Perjeta), trastuzumab (Herceptin), or chemotherapy.

Additionally, there are patients who are able to achieve a good response with fewer treatments, and those patients need to be selected, Pusztai adds.